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Introduction
Atherosclerotic lesion formation, progression, and plaque rupture are the underlying causes of cardiovascular 
disease (CVD) in the developed world (1, 2). In a healthy, unobstructed blood vessel, endothelial cells (ECs) line 
the vascular wall and act as the first layer of defense against vascular damage and immune cell recruitment that 
contributes to the early stages of atherosclerosis. EC dysfunction, induced by mechanical strain, local inflamma-
tion, and/or the uptake of modified lipoproteins is a major contributing factor to the initiation and growth of  
atherosclerotic lesions (1). Molecular and physiologic changes to the vascular endothelium, including secretion 
of proinflammatory mediators and recruitment of monocytes into the blood vessel wall are important contribu-
tors to the early molecular and cellular events in atherogenesis (2). Moreover, enhanced expression of adhesion 
molecules ICAM-1 and VCAM-1 on the surface of lesion-resident ECs is crucial for the capture and transmigra-
tion of leukocytes into the subendothelial space of developing atherosclerotic lesions (1).
As a means of  characterizing unique surface proteins present on atherosclerotic lesions in vivo, Liu 
et al. screened a phage-display random peptide library and identified csGRP78 (3). Although GRP78 was 
observed on the surface of  lesion-resident ECs in the aortas from ApoE–/– mice and in human lesions from 
The 78-kDa glucose-regulated protein (GRP78) is an ER molecular chaperone that aids in protein 
folding and secretion. However, pathological conditions that cause ER stress can promote the 
relocalization of GRP78 to the cell surface (csGRP78), where it acts as a signaling receptor to 
promote cancer progression. csGRP78 also possesses antigenic properties, leading to the production 
of anti-GRP78 autoantibodies, which contribute to tumor growth. In contrast, the presence and role 
of anti-GRP78 autoantibodies in atherosclerosis is unknown. Here, we show that atherosclerotic-
prone ApoE–/– mice develop circulating anti-GRP78 autoantibodies that bind to csGRP78 on lesion-
resident endothelial cells. Moreover, GRP78-immunized ApoE–/– mice exhibit a marked increase 
in circulating anti-GRP78 autoantibody titers that correlated with accelerated lesion growth. 
Mechanistically, engagement of anti-GRP78 autoantibodies with csGRP78 on human endothelial 
cells activated NF-κB, thereby inducing the expression of ICAM-1 and VCAM-1, a process blocked by 
NF-κB inhibitors. Disrupting the autoantibody/csGRP78 complex with enoxaparin, a low-molecular-
weight heparin, reduced the expression of adhesion molecules and attenuated lesion growth. In 
conclusion, anti-GRP78 autoantibodies play a crucial role in atherosclerosis development, and 
disruption of the interaction between anti-GRP78 autoantibodies and csGRP78 represents a 
therapeutic strategy.
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iliac artery segments, a causal role for csGRP78 in lesion development has not as yet been established (3). 
Studies investigating the function of  csGRP78 in cancer cell proliferation and tumor growth have report-
ed that it acts as a membrane-associated receptor (4), thereby mediating a variety of  signaling pathways 
through its association with assorted ligands and coreceptors (5). Recent evidence has highlighted the role 
of  csGRP78 as a regulator of  cancer cell survival and proliferation upon interaction with α2-macroglobulin 
through PI3K/AKT signaling (6), while conversely highlighting a role for csGRP78 in inducing apop-
tosis through suppression of  Ras/MAPK when bound by extracellular Par-4 (7). Our own recent find-
ings have demonstrated the ability of  csGRP78 to activate tissue factor procoagulant activity by mediating 
Ca2+ release from the ER via PLC-mediated IP3 production (8, 9). It remains unknown, however, whether 
csGRP78 plays a role in atherosclerotic lesion growth and progression.
While the precise molecular mechanism by which GRP78 translocates to the cell surface remains 
unclear (10), it has recently been shown that induction of  ER stress may actually stimulate such relocal-
ization (11). Given that ER stress is a known hallmark of  atherosclerotic lesion progression (12–14), a link 
between csGRP78 in ECs and atherogenesis is tantalizingly plausible. The presence of  csGRP78 can also 
induce the production of  anti-GRP78 autoantibodies by the humoral immune system (15). Autoantibodies 
to GRP78 have been identified circulating in the peripheral blood of  patients with a variety of  cancers, 
including melanoma, prostate cancer, and ovarian cancer (15). Although anti-GRP78 autoantibodies that 
recognize both the N- and C-terminal regions of  GRP78 have been found, it is important to note that the 
majority of  the anti-GRP78 autoantibodies found in the human circulation are directed against a specific 
epitope on the N-terminus of  surface GRP78 (Leu98-Leu115), indicating the relevance of  this particular 
antigenic region (16). Moreover, high levels of  these anti-GRP78 autoantibodies in patients correlate with 
advanced disease and poor survival outcomes, at least in patients with prostate cancer (15). In addition, 
we have demonstrated the presence of  an anti-GRP78 autoantibody/csGRP78 molecular circuit in blad-
der carcinoma cells (8) and, more recently, in prostate cancer (9). Furthermore, the low-molecular-weight 
heparin (LMWH) enoxaparin (17) binds to csGRP78, thereby disrupting the engagement of  anti-GRP78 
autoantibodies and attenuating their effect on increased rate of  tumor growth (9).
The correlation between anti-GRP78 autoantibodies and atherosclerosis and whether the mechanism 
observed in cancer is relevant to atherosclerotic lesion development have not yet been examined. Here, we 
show that induction of  ER stress results in increased amounts of  csGRP78 in cultured human aortic ECs 
(HAECs). Moreover, we identify anti-GRP78 autoantibodies specific to the N-terminus of  csGRP78 in 
the ApoE–/– mouse model of  atherosclerosis and demonstrate that autoantibody levels correspond to ath-
erosclerotic lesion progression; in addition, activation of  csGRP78 by anti-GRP78 autoantibodies induces 
proinflammatory mediators and adhesion molecule expression in HAECs expressing csGRP78. Finally, 
increasing the circulating levels of  anti-GRP78 autoantibodies accelerates atherosclerotic lesion growth in 
ApoE–/– mice through a direct activation of  csGRP78 on lesion-resident ECs, an effect that is attenuated by 
enoxaparin. These findings provide a solid foundation for understanding the role of  anti-GRP78 autoanti-
bodies and the activation of  csGRP78 in EC function during atherogenesis.
Results
The development of  atherosclerotic lesions correlates with increased anti-GRP78 autoantibody titers. Mice with ath-
erosclerotic lesions exhibit increased levels of  anti-GRP78 autoantibodies. High levels of  anti-GRP78 auto-
antibodies identified in prostate cancer patients were shown to correlate with accelerated cancer progression 
and reduced overall survival (15). Although csGRP78 has been identified on atherosclerotic lesion-resident 
ECs in mice and humans (3), the role of  anti-GRP78 autoantibodies was not assessed in this pathological 
setting. To investigate whether anti-GRP78 autoantibody levels correlate with accelerated lesion develop-
ment, repeated blood draws from ApoE–/– and control C57BL/6 mice were taken between 8 and 20 weeks 
of  age, a marked period of  lesion growth in ApoE–/– mice but not for otherwise isogenic C57BL/6 wild-type 
control mice. We observed that anti-GRP78 autoantibody titers increased with age in ApoE–/– mice fed a 
chow diet and were much higher than levels in C57BL/6 mice at 20 weeks of  age (Figure 1A). To examine 
whether the timing of  lesion development could influence anti-GRP78 autoantibody titers, mice were fed a 
high-fat diet (HFD) that markedly accelerates atherosclerosis progression. ApoE–/– mice on a HFD showed 
much higher titers of  anti-GRP78 autoantibodies compared with C57BL/6 mice at 17 weeks of  age (Figure 
1B), suggesting a more rapid induction of  anti-GRP78 autoantibodies under dietary conditions that induce 
atherosclerosis. In contrast, 4-PBA, a small chemical chaperone known to reduce ER stress and lesion 
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development (18, 19), blocked atherosclerotic lesion growth and reduced anti-GRP78 autoantibody titers 
in ApoE–/– mice (Supplemental Figure 1; supplemental material available online with this article; https://
doi.org/10.1172/jci.insight.99363DS1).
Anti-GRP78 autoantibodies bind to atherosclerotic lesion-resident ECs in ApoE–/– mice. To determine whether 
anti-GRP78 autoantibodies interact with lesion-resident ECs, 18-week-old ApoE–/– mice were administered 
i.v. via the tail vein with biotinylated anti-GRP78 autoantibodies (b-anti-GRP78 autoantibodies) or bioti-
nylated mouse IgG (b-IgG) and euthanized after 30 minutes. The ascending aorta and proximal arch were 
dissected and double-stained en face for ECs (anti-CD31) and for the presence of  biotinylated antibodies 
(Alexa Fluor 594 Streptavidin). Binding of  b-anti-GRP78 autoantibodies was assessed in regions with high 
probability (HP) and low probability (LP) of  developing lesions (Figure 1C), as described by Iiyama et al. (20). 
We observed that b-anti-GRP78 autoantibodies bound to lesion-resident ECs in HP regions (Figure 1D; top 
middle) but not in LP regions (Figure 1D; left). To confirm the binding specificity, no signal was detected in 
either LP or HP regions from mice receiving b-IgG (Figure 1D; bottom) or in HP regions incubated with sec-
ondary antibodies only (Figure 1D; top right). These results provide evidence that anti-GRP78 autoantibodies 
directly interact with atherosclerotic lesion-resident ECs in ApoE–/– mice. Finally, we measured anti-GRP78 
autoantibody titers in patients with established CVD and compared them to age-matched control patients 
without CVD. Similar to our in vivo studies, CVD patients had significantly elevated levels of  anti-GRP78 
autoantibody titers when compared with healthy, aged-matched controls (Figure 1E). These data provide 
clear evidence that autoantibody titers correlate with atherosclerotic lesion development both in mice and in 
humans and that anti-GRP78 autoantibodies bind csGRP78 on the surface of  lesion-resident ECs.
Elevated levels of  anti-GRP78 autoantibodies exacerbate atherosclerosis in ApoE–/– mice. In order to increase the lev-
els of circulating anti-GRP78 autoantibodies in vivo and determine whether they play a role in lesion develop-
ment, 6-week-old ApoE–/– mice on a chow diet were immunized with recombinant GRP78 (rGRP78) or control 
ovalbumin (OVA). ApoE–/– mice receiving rGRP78 produced much higher levels of anti-GRP78 autoantibodies 
at both 12 and 15 weeks of age compared with control OVA-immunized mice (Figure 2A). Atherosclerotic lesion 
development was measured by histologic quantification of lesion size at the aortic root as described previously 
(21). Mice with higher anti-GRP78 autoantibody titers (rGRP78 immunized) had much larger lesions compared 
with control OVA-immunized mice (Figure 2, B and C). Quantification of the necrotic area in lesions demon-
strated a much greater degree of necrosis in mice with higher levels of anti-GRP78 autoantibodies (Figure 2D). 
To further characterize the progression of atherosclerosis, lesions were scored based on criteria described by van 
Vlijmen et al. (22) and assigned to 3 categories: (a) early lesions consisting of only fatty streaks containing foam 
cells; (b) moderate lesions characterized by extension into the media and mild fibrosis; and (c) advanced lesions 
containing cholesterol clefts and necrotic area deeper into the media. Mice with higher anti-GRP78 autoanti-
body titers had more advanced lesions and fewer early lesions compared with control OVA-immunized mice 
(30% vs. 17% and 29% vs. 44%, respectively, Figure 2E). Plasma triglyceride (Figure 2F) and total cholesterol 
(Figure 2G) levels were not different between the groups, indicating that differences in lesion growth and severity 
are not the result of alterations in circulating lipid levels. Taken together, these results indicate that elevated levels 
of anti-GRP78 autoantibodies contribute to atherosclerotic lesion development.
ER stress inducers increase of  the levels of  csGRP78 on ECs. Previous reports have shown that ER stress is suf-
ficient to cause cell-surface expression of GRP78 in cancer cell lines (11, 23). Consistent with these findings, 
primary HAECs treated with thapsigargin (Tg; 300 nM) or tunicamycin (Tm; 2.5 μg/ml) for 16, 24, or 32 hours 
exhibited increased levels of GRP78 in surface fractions (sGRP78). This increase peaked at 16 and 24 hours 
after induction of ER stress (Figure 3, A and B). Consistent with previous studies, CD31, a surface marker 
of ECs, is downregulated under conditions of ER stress (24). The induction of ER stress by both Tg and 
Tm in HAECs was confirmed by the increased protein expression of total GRP78, IRE1α, and p-eIF1α. To 
investigate whether physiologically relevant factors could stimulate csGRP78 expression in ECs, HAECs were 
exposed to well-established natural inducers of ER stress, including lipid oxidation products, 7-ketocholesterol 
and 4-HNE (25), as well as to the inducers of oxidative stress, Sin-1 and peroxynitrite (26). Increased csGRP78 
expression was also observed under these conditions (Figure 3C). Consistent with these in vitro results and our 
previous findings (12, 13), early atherosclerotic lesions from chow-fed 12-week-old ApoE–/– mice, defined as 
fatty streaks (Supplemental Figure 2), showed the presence of physiological inducers of ER stress, including 
free cholesterol (filipin staining) and peroxynitrite (3-nitrotyrosine staining) (Supplemental Figure 3), as well as 
increased expression of several ER stress markers, including GRP78 itself, calreticulin, CHOP, pPERK, and 
TDAG51 in atherosclerotic lesion-resident macrophages and ECs (Supplemental Figure 4).
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Figure 1. Anti-GRP78 autoantibodies are elevated in ApoE–/– mice. Serum levels of anti-
GRP78 autoantibodies were measured by ELISA in female C57BL/6 and ApoE–/– mice on 
either a chow (A) or HFD (B) (n = 7–9 per group). *P < 0.05 versus age-matched C57BL/6 
mice, 2-tailed t test. All data are presented as a ratio of absorbance units (AU) relative 
to a standard sample. Representative images of aortic root sections from mice in A and 
B are presented; arrows indicate atherosclerotic lesions. Original magnification, ×10. (C) 
Location of LP and HP regions on the ascending aorta and proximal arch assessed for 
atherosclerotic lesions and presence of bound anti-GRP78 autoantibodies. (D) Represen-
tative immunofluorescence images of anti-GRP78 autoantibody binding to lesion-resi-
dent ECs in the aortic arch of ApoE–/– mice. Mice were injected i.v. with 10 μg b-anti-GRP78 
autoantibodies or b-IgG and euthanized 30 minutes after injection. Multiple pieces from 
LP and HP regions of the arch were dissected for each mouse and stained en face, and 3 
images per region were qualitatively assessed for the presence/absence of anti-GRP78 
autoantibody or IgG staining in lesion and nonlesion areas. Dashed lines indicate lesion 
areas. ECs are stained in green (rat anti-mouse CD-31) and anti-GRP78 autoantibodies or 
IgG are stained in red (streptavidin-conjugated secondary antibody). Nuclei are coun-
terstained with DAPI (blue). One anti-GRP78 autoantibody and one b-IgG mouse were 
injected in parallel for each experiment. Original magnification, ×40. (E) Anti-GRP78 auto-
antibody titers in a clinical population with established CVD and age-matched controls, as 
measured by ELISA (n = 12). *P < 0.05 versus age-matched controls, 2-tailed t test.
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Anti-GRP78 autoantibodies increase adhesion molecule expression and induce leukocyte adhesion. Given that 
anti-GRP78 autoantibody titers increase during atherosclerotic lesion development, we investigated wheth-
er anti-GRP78 autoantibodies trigger a proatherogenic response in cultured ECs. Figure 4A demonstrates 
that anti-GRP78 autoantibodies can induce the expression of  ICAM1 and VCAM1 in a dose-dependent 
manner. To clearly delineate the role of  anti-GRP78 autoantibodies on increased expression of  these 
adhesion molecules, HAECs were pretreated with Tm for 24 hours to increase csGRP78 expression and 
subsequently exposed to anti-GRP78 autoantibodies. Treatment with anti-GRP78 autoantibodies resulted 
in much higher mRNA expression of  ICAM1 and VCAM1 compared with Tm or IgG controls (Figure 
4B). Furthermore, incubation of  anti-GRP78 autoantibodies with a synthetic conformational peptide (CP; 
sequence CNVSKDSC) (8, 15) that binds anti-GRP78 autoantibodies and blocks signaling of  csGRP78 
clearly reduced ICAM1 and VCAM1 expression (Figure 4B). Our studies with prostate cancer showed that 
enoxaparin (27), an FDA-approved low-molecular-weight heparin anticoagulant, can inhibit the binding 
of  anti-GRP78 autoantibody to csGRP78. Likewise, enoxaparin was effective in specifically blocking the 
increased expression of  ICAM1 and VCAM1 in HAECs elicited by the anti-GRP78 autoantibodies (Figure 
4C). Expression of  cell adhesion molecules on ECs is critical for monocyte recruitment into atheroscle-
rotic lesions (28, 29). Therefore, we examined whether the anti-GRP78 autoantibody-induced increase 
in ICAM1 and VCAM1 expression affected the adhesion of  human monocyte-derived cells (U937) to 
HAECs. Treatment of  HAECs with Tm followed by anti-GRP78 autoantibodies markedly increased the 
number of  attached U937 cells compared with control isogenic IgG-treated cells (Figure 4D). Treatment 
with Tm or anti-GRP78 autoantibodies alone had no effect on U937 cell attachment. Consistent with the 
effects seen on adhesion molecule expression, addition of  the CP specifically reduced U937 attachment to 
HAECs. As expected, TNF-α treatment clearly increased U937 attachment to HAECs.
Anti-GRP78 autoantibodies promote proinflammatory gene expression and adhesion molecule expression via the 
NF-κB pathway. To determine potential pathways activated by anti-GRP78 autoantibodies, we utilized the 
NanoString technology. Examining ECs treated with anti-GRP78 autoantibodies revealed that inflam-
matory cytokines are upregulated (Figure 5A). Inflammation is directly linked to cell adhesion molecule 
Figure 2. Atherosclerotic lesion growth is accelerated in ApoE–/– mice with elevated anti-GRP78 autoantibody titers. (A) Serum levels of anti-GRP78 
autoantibodies were measured by ELISA in female ApoE–/– mice fed a chow diet and injected 3 times at 10-day intervals with 50 μg/ml OVA or rGRP78 
beginning at 6 weeks of age. Data are presented as a ratio of absorbance units (AU) relative to a standard sample (n = 6 per group). *P < 0.05 versus OVA 
at each time point, 2-tailed t test. (B) Quantification of atherosclerotic lesion size at the aortic root from 15-week-old immunized mice. Lesion size was 
measured in 5–6 sections at 80-μm intervals (n = 6 per group). *P < 0.01 versus OVA immunized mice, 2-tailed t test. (C) Representative cross-section 
images of the aortic root stained with H&E for each treatment group. Arrows indicate atherosclerotic lesions. Original magnification, ×10. Scale bar: 
100 μm. (D) Quantification of necrotic area in lesions at the aortic root. Data are expressed as percentage of total lesion area (n = 6 per group). *P < 0.01 
versus OVA treated mice, 2-tailed t test. (E) Classification of atherosclerotic lesions in ApoE–/– mice immunized with OVA or rGRP78. Plasma levels of (F) 
triglycerides and (G) total cholesterol were measured in immunized ApoE–/– mice at 15 weeks of age by colorimetric assays (n = 6–8 per group).
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expression in ECs (30), and this is regulated by the NF-κB signaling pathway (31). To delineate the contri-
bution of  NF-κB to the activation of  ECs by anti-GRP78 autoantibodies, we examined the expression of  a 
panel of  cytokines and chemokines known to be induced by NF-κB. In addition to treating cells with anti-
GRP78 autoantibodies, a cotreatment strategy with NF-κB inhibitors (TPCA-1, BAY 11-7082, SC-514, 
JSH-23) was conducted and mRNA expression was measured by quantitative RT-PCR (8). mRNA levels 
of  VCAM1 (Figure 5B), ICAM1 (Figure 5C), cytokines IL-1β (Figure 5D) and IL-6 (Figure 5E), and the 
chemokine MIP-1α (Figure 5F) were much higher in anti-GRP78 autoantibody-treated HAECs compared 
with IgG-treated cells. Pretreatment of  cells with these various NF-κB inhibitors was shown to decrease 
the expression of  cell adhesion molecules, cytokines, and chemokines (Figure 5, B–F). To confirm that 
NF-κB plays a role in anti-GRP78 autoantibody-mediated signaling, ECs expressing csGRP78 were pre-
treated with the NF-κB activation inhibitor II, JSH-23, for 2 hours followed by anti-GRP78 autoantibodies 
or human IgG. NF-κB inhibition reduced anti-GRP78 autoantibody-mediated induction of  ICAM-1 and 
VCAM-1 expression (Figure 5, B and C). In addition, treatment with JSH-23 reduced monocyte adhesion 
to HAECs treated with anti-GRP78 autoantibodies (Figure 5G), further supporting the functional involve-
ment of  the NF-κB pathway in the anti-GRP78 autoantibody/csGRP78 molecular circuit. Consistent with 
these in vitro findings, the expression of  p65 subunit of  NF-κB was noticeably increased in atherosclerotic 
sections from ApoE–/– mice immunized with full-length, functionally active rGRP78 compared with control 
mice immunized with OVA (Supplemental Figure 5).
Enoxaparin or TPCA-1 inhibits the effect of  anti-GRP78 autoantibody on NF-κB p65 subunit nuclear translo-
cation. Our data indicate that NF-κB activation may be required for anti-GRP78 autoantibody-induced 
expression of  proinflammatory markers in HAECs. To further investigate this phenomenon, we evaluated 
the localization of  the NF-κB p65 subunit within the ECs by immunofluorescence. Similar to the TNF-α–
positive control for NF-κB activation, treatment of  HAECs with anti-GRP78 autoantibodies elicited nucle-
ar translocation of  the p65 subunit (Figure 6A), a hallmark of  NF-κB transcriptional activation. However, 
this finding was reversed when cells were pretreated with enoxaparin or TPCA-1 (Figure 6, A and B). 
Finally, we utilized immunoblotting to examine IκBα (a marker of  the canonical NF-κB pathway) and p100 
(a marker of  the noncanonical NF-κB pathway) expression following anti-GRP78 autoantibody treatment 
(Figure 6C). A decrease in the protein expression of  IκBα, but not p100, was observed after anti-GRP78 
autoantibody treatment (Figure 6C), suggesting that the NF-κB canonical pathway is the main driver of  this 
activation; TNF-α treatment served as a positive control as described previously (29).
Direct injection of  anti-GRP78 autoantibodies into ApoE–/– mice accelerates atherosclerotic lesion growth. To 
directly elucidate the effect of  anti-GRP78 autoantibodies on the rate of  lesion growth in mice, we inject-
ed ApoE–/– mice with patient-purified anti-GRP78 autoantibodies to achieve a pathologic dose of  60 μg/
Figure 3. ER stress causes an increase in csGRP78 levels on ECs. HAECs were treated with (A) 2.5 μg/ml Tm or (B) 300 nM Tg for the indicated time period 
or with (C) 7-ketocholesterol (7KC), Sin-1, 4-hydroxynonenal (4HNE), or peroxynitrite (Peroxy) for 8 hours, after which surface proteins were biotinylat-
ed and separated by streptavidin pull down. Total cell lysates (tGRP78) and surface protein fractions (sGRP78) were subjected to Western blotting for 
detection of GRP78, the EC marker CD31, IRE1α, or phospho-eIF1α. Blots were also immunostained for β actin as a protein loading control. Densitometry 
quantification is indicated under each band relative to untreated cells and normalized to β-actin.
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ml (9, 16). Enoxaparin cotreatment, used as an intervention approach, reversed the positive effect of  the 
anti-GRP78 autoantibodies on lesion growth. Representative images of  the treatment groups (Figure 7, 
A and B), along with quantification of  plaque volume for all the acquired images (Figure 7C), are shown. 
We further evaluated NF-κB activation by identifying ECs with positive p65 subunit nuclear staining. Only 
the anti-GRP78 autoantibody-treated group exhibited enhanced p65 subunit–positive nuclei staining in 
atherosclerotic lesion-resident ECs (Figure 7D). In support of  our cell culture studies, enoxaparin reduced 
p65 immunostaining of  lesion-resident ECs (Figure 7D, AA+Enox). These findings suggest that the direct 
i.v. administration of  anti-GRP78 autoantibodies in mice promotes atherosclerotic lesion progression, a 
pathological process specifically mitigated by enoxaparin.
Discussion
Atherosclerosis contributes to the development of cardiovascular pathologies that can lead to serious complica-
tions, including stroke or myocardial infarction (2, 32). Developing a sound understanding of the mechanism 
of atherosclerotic lesion growth and plaque stability provides important insights for designing new therapeutics 
that can decrease the burden of human CVD and its complications. This study provides compelling evidence for 
the role of an anti-GRP78 autoantibody/csGRP78 signaling circuit on ECs as drivers of atherosclerotic lesion 
growth and possibly plaque rupture. Under pathological conditions, such as atherosclerosis and cancer, GRP78 
has been identified on the surface of many cell types, but the precise cellular events that allow its evasion from 
ER retention mechanisms and consequent translocation to the plasma membrane are not entirely understood. 
GRP78 possesses the classic C-terminal Lys-Asp-Glu-Leu (KDEL) sequence that is recognized by the KDEL 
receptor on the ER lipid bilayer, thereby resulting in selective retrograde transport back to the ER from the Golgi 
(33, 34). One possible explanation is that the KDEL receptor is overwhelmed as a result of its saturation due to 
chronic or acute ER stress, allowing proteins containing the KDEL sequence to escape to the cell surface (35, 
36). It is also possible that conditions of ER stress modify the structure of GRP78 or its interaction with specific 
binding partners that would allow for its movement from the ER to the cell surface. GRP78 was first identified 
on the surface of lesion-resident ECs by Liu et al. (3) by using a phage-display peptide library to screen for novel 
surface markers specifically present on atherosclerotic lesions. While this was the first indication that GRP78 
might have an alternative role in atherosclerosis other than its conventional role in ER stress and the UPR per 
se, the underlying cellular mechanism by which csGRP78 modulates atherogenesis as well as the detection and 
effect of circulating anti-GRP78 autoantibodies was not investigated.
Our previous studies show that csGRP78 signaling promotes cancer cell proliferation (8) and accel-
erates tumor growth (9), which raised the question as to whether activation of  csGPR78 via anti-GRP78 
autoantibodies can also contribute to atherosclerotic lesion development and progression. We systematical-
ly investigated how this interaction could modulate EC function and atherosclerotic lesion development in 
ApoE–/– mice (summarized in Figure 8). The observation that ApoE–/– mice, a well-established mouse model of  
atherosclerosis (13, 19), have elevated anti-GRP78 autoantibody titers that correlate with lesion growth, com-
pared with age-matched C57BL/6 mice, suggests a link between the progression of  atherosclerotic lesions and 
anti-GRP78 autoantibody levels. In support of  these findings, we observed that the acceleration in atheroscle-
rotic lesion growth correlated with an increase in autoantibody titers in ApoE–/– mice placed on a HFD com-
pared with chow-fed ApoE–/– mice. The association between anti-GRP78 autoantibodies and atherosclerotic 
lesion development supports the concept that anti-GRP78 autoantibodies modulate and accelerate the forma-
tion of  advanced lesions. Further, although C57BL/6 mice on the chow diet do not develop atherosclerosis 
when fed a HFD, these mice demonstrated detectable levels of  circulating anti-GRP78 autoantibodies. Thus, 
it is possible that csGRP78 is expressed on ECs within fatty streaks of  C57BL/6 mice, thereby contributing 
to the detectable levels of  GRP78 autoantibodies reported here. Clinically, increased levels of  anti-GRP78 
autoantibodies were detected in a cohort of  patients with established CVD, compared with healthy, aged-
matched controls. This clinical observation parallels our in vivo findings and hint to the idea that a threshold 
level of  circulating anti-GRP78 autoantibodies is required to elicit csGRP78-mediated EC activation. Indeed, 
a threshold of  anti-GRP78 autoantibodies is required for tumor cell proliferation (8) and growth (9); addition-
ally, these autoantibody levels in mice correspond to titers seen in patients (15, 16).
Additional evidence to indicate a role of  anti-GRP78 autoantibodies in atherosclerosis was 
demonstrated by the direct binding of  anti-GRP78 autoantibodies to lesion-resident ECs within the 
aortic root. No detectable binding of  these autoantibodies was observed on the surface of  ECs distal 
to the atherosclerotic lesion, thus suggesting that conditions within the lesion environment that induce 
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ER stress increase csGRP78 levels. This is further supported by increased expression of  csGRP78 
following treatment of  HAECs with well-established lesion-resident agents/conditions known to elicit 
an ER stress response, including 7-ketocholesterol and peroxynitrite as well as csGRP78 expression on 
lesion-resident ECs (ref. 3 and Supplemental Figure 4).
To further understand the contribution of  anti-GRP78 autoantibodies to atherogenesis, ApoE–/– mice were 
immunized with rGRP78 to increase anti-GRP78 autoantibody titers. Six-week-old ApoE–/– mice immunized 
against rGRP78 presented with higher anti-GRP78 autoantibody levels and had much larger lesions at 15 
weeks of  age compared with OVA-injected control mice. It is worth noting that both cohorts had similar plas-
ma cholesterol and triglyceride levels, data that suggest that increased lesion size was not due to a change in 
circulating lipids. Mice with higher levels of  anti-GRP78 autoantibodies also demonstrated a larger necrotic 
core area in lesions. Lipid-rich necrotic cores are considered a key feature of  advanced lesions and correspond 
to increased instability of  atherosclerotic plaques (37), suggesting that anti-GRP78 autoantibodies amplify 
lesion progression to a more complex and unstable state. Together, these findings suggest that anti-GRP78 
autoantibodies exacerbate lesion development through interaction with lesion-resident ECs.
In this report, we demonstrate that anti-GRP78 autoantibody-mediated activation of  csGRP78 stim-
ulates expression of  ICAM1 and VCAM1 as well as increased adhesion of  monocytes to ECs. Based on 
these findings, we investigated two means of  neutralizing the effect anti-GRP78 autoantibodies: a syn-
thetic conformational peptide, CNVSKDSC, which mimics the N-terminal domain of  GRP78 (15), and 
enoxaparin, a LMWH that can bind to GRP78 directly (38). Both approaches were effective in specifically 
neutralizing the effect of  anti-GRP78 autoantibodies on increased expression of  adhesion molecules. This 
observation confirms and provides a likely mechanism to explain the findings in previous studies reporting 
that LMWH intervention minimized the atherogenic diet-induced histopathological lesions in heart, liver, 
and kidney tissues of  rats (39–41). Expression of  adhesion molecules as well as the binding and transmi-
gration of  leukocytes into the subendothelial space are critical steps during the early stages of  atherogenesis 
and are considered hallmarks of  EC activation (2, 32). These findings strongly suggest that anti-GRP78 
autoantibodies contribute to EC activation, lesion development, and progression.
Inflammation leads to recruitment of leukocytes to the surface of lesion-resident ECs, and the observed 
leukocyte/EC interactions, such as capture, rolling, and firm adhesion, can be viewed as a series of overlap-
ping synergistic interactions among adhesion molecules, resulting in an adhesion cascade. These cascades direct 
leukocyte migration, which is essential for the generation of effective inflammatory responses and the develop-
ment of rapid immune responses (30). The expression of the adhesion molecules is orchestrated by the NF-κB 
pathway; this is not only present in human atherosclerotic lesions, but also contributes to the pathogenesis of  
atherosclerosis (42, 43). Given that NF-κB has been shown to regulate the expression of adhesion molecules in 
ECs (31), we investigated the role of NF-κB based on the induction of adhesion molecule expression, including 
ICAM1 and VCAM1, induced by the autoantibodies. Expression of cytokines and chemokines occurs during 
EC activation and has also been shown to be regulated by NF-κB (42). In support of an involvement of NF-κB 
in anti-GRP78 autoantibody-mediated csGRP78 signaling, we observed increased expression of known proin-
flammatory mediators, activated by NF-κB, in cells treated by anti-GRP78 autoantibodies. Further, we now 
demonstrate that EC activation by anti-GRP78 autoantibodies can be specifically reversed with either enoxapa-
rin or NF-κB pathway inhibitors. Additional evidence supporting a connection between anti-GRP78 autoanti-
bodies and NF-κB was recently described by Shimizu et al. (44) in brain microvascular ECs exposed to antibod-
ies isolated from patients diagnosed with the autoimmune disorder neuromyelitis optica. Consistent with our 
experimental results, antibodies targeting csGRP78 activated NF-κB and induced ICAM1 expression; however, 
anti-GRP78 autoantibody titers were not determined in that study (44). Nevertheless, these findings emphasize 
that both anti-GRP78 autoantibodies and csGRP78 are required for NF-κB activation in lesion-resident ECs and 
this molecular mechanism contributes to lesion development and possibly plaque rupture.
Additional studies to identify the precise upstream molecular signals that connect NF-κB to anti-GRP78 
autoantibody-stimulated csGRP78 signaling are actively being explored. Some potential pathways have been 
discussed here; however, their relevance in ECs remains to be established. Previous findings demonstrated an 
association between csGRP78 and a G protein complex at the plasma membrane of  stimulated macrophages 
(45). It is known that activation of  the heterotrimeric G protein leads to PKC activation, which in turn results 
in canonical IKK/NF-κB activation in ECs (46, 47). In addition, our group has demonstrated the ability 
of  anti-GRP78 autoantibodies to activate csGRP78 in bladder carcinoma cells, resulting in PLC-mediated 
release of  Ca2+ from ER stores (8). Although the mechanism is not completely understood, it is thought 
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that an increase in cytosolic Ca2+ activates NF-κB, 
possibly through production of  mitochondrial 
reactive oxygen species (48, 49). Finally, recent 
studies utilizing therapeutically resistant cancer 
cells showed that csGRP78 complexes with PI3K 
as well as the ability of  anti-GRP78 autoantibod-
ies to induce csGRP78-driven PI3K-dependent 
AKT activation (16, 23). In ECs, NF-κB activa-
tion is known to be mediated by PI3K/AKT in 
response to TNF-α (50). Further work is currently 
being performed to characterize the molecular 
signals in ECs linking anti-GRP78 autoantibody/
csGRP78 circuit with NF-κB activation.
Chronic inflammation contributes to ath-
erogenesis and CVD; a number of  antibodies 
targeting self-antigens, such as autoantibodies 
against apolipoprotein A-1 (apoA-1) or oxi-
dized LDL, have been associated with athero-
sclerosis, even in the absence of  overt immu-
nization or additional infection, leading to the 
theory that atherosclerosis could fundamen-
tally be an autoimmune disease (51–54). Clin-
ical evidence indicates that elevated levels of  
anti–apoA-1 antibodies correspond to a worse 
prognosis (55), supporting the idea that proin-
flammatory autoantibodies have a causal role 
in CVD. Similarly, high levels of  anti-GRP78 
autoantibodies in prostate cancer patients cor-
relate with advanced disease and poor overall 
survival (15), although it remains to be determined whether the elevated levels of  anti-GRP78 autoanti-
bodies that we observed in patients with established CVD affect disease progression and plaque stability. 
Growing evidence supporting the role of  autoantibodies in CVD and as a bona fide prognostic mark-
er (56) highlights the need to identify new relevant targets, such as anti-GRP78 autoantibodies and to 
explore the potential therapeutic benefits of  modulating their deleterious effects.
Figure 4. ER stress and anti-GRP78 autoantibod-
ies synergistically enhance ICAM1 and VCAM1 
expression. (A) Treatment of HAECs with increasing 
concentrations of anti-GRP78 autoantibody increases 
ICAM1 and VCAM1 mRNA expression, as measured by 
qRT-PCR. *P < 0.05 versus untreated cells. Total RNA 
was isolated from HAECs pretreated without or with 
2.5 μg/ml Tm for 24 hours. Cells were then exposed 
to purified anti-GRP78 autoantibodies (AA, 60 μg/
ml) or human IgG (60 μg/ml) for 8 hours without 
or with (B) CNVSKDSC peptide (CP, 90 μg/ml) (†P < 
0.05 versus all other groups) or (C) enoxaparin (Enox, 
50 μg/ml) (*P < 0.05 versus nontreated cells). (D) 
Adhesion of BCECF-AM–loaded U937 cells to HAECs 
treated as described in A, with representative images. 
Scale bar: 400 μm. HAECs treated with TNF-α (100 
ng/ml, 8 hours) served as a positive control. Data 
are expressed as percentage adhesion relative to 
untreated cells (n = 3 per group). *P < 0.05 versus all 
other groups. †P < 0.05 versus all other groups. #P < 
0.05 versus all other groups. ANOVA and t test were 
used for all statistical comparisons.
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Collectively, our results present a role for an anti-GRP78 autoantibody/csGRP78 signaling circuit in 
EC activation in early stages of  atherosclerotic lesion development. To our knowledge, this work is the 
first to define a mechanism by which csGRP78 signaling accelerates atherogenesis. Translational strategies 
aimed at blocking csGRP78 signaling, possibly via the neutralization of  circulating anti-GRP78 autoanti-
bodies, have the potential of  attenuating atherosclerotic lesion development in clinical applications.
Figure 5. Increased mRNA expression of ICAM1 and VCAM1 by anti-GRP78 autoantibodies in ECs is mediated by NF-κB. (A–F) Relative mRNA levels of 
cytokines and chemokines, ICAM1 and VCAM1, determined by qRT-PCR of HAECs treated with anti-GRP78 autoantibodies (AA, 60 μg/ml) or human IgG 
(60 μg/ml) and/or NF-κB inhibitors (TPCA-1, BAY 11-7082, JSH-23, SC-514). TNF-α was used as a positive control. Data are expressed as fold change relative 
to IgG-treated cells (n = 3 per group). *P < 0.05 versus all other groups. #P < 0.01 versus anti-GRP78 autoantibody treatment alone. (G) Adhesion of BCE-
CF-AM–loaded U937 cells to HAECs treated JSH-23 with or without anti-GRP78 autoantibodies. Representative images are shown. Scale bar: 400 μm. Data 
are expressed as percentage cell adhesion relative to Tm-treated cells (n = 3 per group). *P < 0.05 versus all other groups. †P < 0.05 versus all other groups. 
ANOVA and t test were used for all statistical comparisons.
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Methods
Animals. Female C57BL/6 and ApoE–/– mice from The Jackson Laboratory were fed either a normal chow 
or HFD ad libitum (Harlan Tekland; 88137), with free access to water. All mouse experiments were blinded 
to reduce observer’s bias and were carried out in compliance with the McMaster Animal Research Ethics 
Board. In all experiments described here, blood was collected from the right ventricle under isoflurane anes-
thesia. Mice were then euthanized by cervical dislocation and immediately perfused with PBS followed by 
Figure 6. Anti-GRP78 autoantibodies induce NF-κB p65 nuclear localization. (A) HAECs were pretreated with either enoxaparin (Enox, 50 μg/ml) or TPCA-
1 (1 μM) for 6 hours prior to treatment with either human IgG (30 μg/ml) or purified anti-GRP78 autoantibody (AA, 30 μg/ml) for 12 hours. Representative 
images of immunofluorescence staining of NF-κB p65 subunit localization are presented. Original magnification, ×20. (B) Quantification of positive p65 
nuclear staining. NF-κB p65 is stained red (Cy5-conjugated secondary antibody). Nuclei were counterstained with DAPI (n = 10 per group). *P < 0.05 versus 
IgG. #P < 0.05 versus anti-GRP78 autoantibody, ANOVA. (C) Anti-GRP78 autoantibody treatment substantially activates the NF-κB classical canonical 
pathway but not the alternative pathway, as determined by immunoblotting for IκBα and p100, respectively. HAECs were treated with human IgG (IgG, 30 
μg/ml) or purified anti-GRP78 autoantibodies (AA, 30 μg/ml) for 6 hours. Total cell lysate were subjected to Western blotting for detection of p100 NF-κB 
subunit or IκBα. Blots were also immunostained for β-actin as a protein loading control. Quantification of immunoblots is expressed as fold change. All 
values are represented as mean ± SD (n = 4–6 per group). *P < 0.05 versus IgG, 2-tailed t test.
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4% paraformaldehyde. The heart and aorta were removed and fixed in buffered formalin overnight before 
further processing. To stimulate the production of  anti-GRP78 autoantibodies, 6-week-old female ApoE–/– 
mice fed a chow diet were injected with 100 μl TiterMax Gold adjuvant emulsified in a 1:1 mixture with 50 
mg endotoxin-free OVA or 50 mg rGRP78 in sterile saline. Mice were given 2 booster injections at a 10-day 
interval. Blood samples were collected at intermediate time points from the submandibular vein. Mice were 
euthanized at 15 or 25 weeks of  age as described above. Total serum cholesterol and triglycerides were mea-
sured with the enzymatic colorimetric assays Cholesterol E and L-Type Triglyceride M, respectively (Wako 
Diagnostics). Human rGRP78 was produced and purified in E. coli as described previously (8).
Cell culture. Primary HAECs were purchased from Clonetics and grown in endothelial growth medium-2 
(EGM-2) supplemented with 1% FBS and growth factors (EGM Bullet Kit, Lonza) at 37°C in 5% CO2. Cells 
at passage 4–8 were treated with 300 nM Tg (MilliporeSigma), 2.5 μg/ml Tm (MilliporeSigma), 100 ng/ml 
TNF-α (R&D Systems), 30 nM NF-κB Activation Inhibitor II (JSH-23; Santa-Cruz), and 60 mg/ml human 
anti-GRP78 autoantibodies; collected; and purified by affinity chromatography as previously described (8), or 
were treated with 60 mg/ml human IgG (MilliporeSigma) or the CNVSKDSC peptide (CanPeptide).
Western blotting. After treatments, HAECs were washed with cold PBS and total lysates were collected in 
SDS-PAGE lysis buffer (60 mM Tris-Cl, pH 6.8, 12.8% glycerol, and 2.05% SDS) containing protease inhibitors 
(Roche). Cell-surface proteins were biotinylated and isolated by the Pierce Cell Surface Protein Isolation Kit 
Figure 7. Enoxaparin intervention neutralizes the effect of anti-GRP78 autoantibody on accelerated atherosclerotic lesion growth in ApoE–/– mice. 
Female C57BL/6 or ApoE–/– mice on a chow diet were injected weekly for 5 weeks with control IgG (168 μg per mouse), anti-GRP78 autoantibody (168 μg 
per mouse), or enoxaparin (enox, 6 μg/kg) (n = 5 per group). Representative images of mouse aortic roots stained with Mason’s trichrome (MT) stain (A), 
hematoxylin/eosin (H&E) (B), and NF-κB p65 nuclear stain (D). (C) Quantification of atherosclerotic lesion size at the aortic root from 15-week-old immu-
nized mice. Lesion size was measured in 5–6 sections at 80 μm intervals (n = 4–5 per group). *P < 0.01 versus IgG treated mice, 2-tailed t test. Scale bar: 
500 μm (A and B); 50 μm (D).
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(Thermo Scientific), as previously described (8). Total lysates and surface fractions were separated on 10% SDS-
PAGE mini-gels and transferred to nitrocellulose membranes. Membranes were incubated overnight at 4°C with 
the following antibodies: GRP78 (BD Transduction), CD31 (Cell Signaling), IRE-1α (Cell Signaling), and β-ac-
tin (MilliporeSigma), followed by incubation with HRP-conjugated secondary antibodies (Bio-Rad) and visual-
ization by Western Lighting Chemiluminescence Reagent (Perkin Elmer) and Kodak X-OMAT Blue XB-1 film.
Immunohistochemistry. Fixed hearts, including the aortic root, were dissected from the aortic arch, cut 
transversely, and paraffin embedded, as previously described (21). One hundred twenty-four–mm-thick 
serial sections were cut through the aortic root. Comparable sections were stained with H&E. Lesion size 
and necrotic area were measured on 4–5 sections at 80-μm intervals using ImageJ (NIH), as previously 
described (21). Necrotic area was expressed as a percentage of  total lesion area. Aortic sections (4-μm 
thick) were deparaffinized, and the endogenous peroxidase activity was blocked with 0.5% H2O2 in meth-
anol for 10 minutes, as described previously (21). Following antigen retrieval where necessary, sections 
were blocked with 5% normal serum, and incubated with the primary antibody for 1 hour, followed by 
biotinylated secondary antibody (Vector Laboratories, Burlingame, CA) diluted 1:500, and streptavidin 
HRP (Vector Laboratories) diluted 1:50. Sections were developed in Nova Red peroxidase substrate (Vector 
Laboratories) and counterstained with hematoxylin. Antibodies directed against NF-κB p65 (ab16502) or 
calreticulin (ab2907) were purchased from Abcam. Antibodies directed against GRP78 (sc-1050), CHOP 
(sc-575), or T cell death–associated gene 51 (TDAG51) (sc-6143) were from Santa Cruz Biotechnology. 
Rabbit anti-phospho-PERK (catalog 3191) was purchased from Cell Signaling. Conditions for antigen 
retrieval and dilution of  antibodies have been described elsewhere (13).
RNA isolation and NanoString analysis. Total RNA was isolated from cells by using the RNeasy Tissue 
Mini Kit (Qiagen). For quality assurance, only samples with RNA integrity numbers greater than 5 were 
used for NanoString analysis. Data were normalized against 7 housekeeping genes, namely, IPO8, GUSB, 
TBP, YWHAZ, ACTB, GAPDH, and RPLP2. P values were corrected for multiple comparisons with the 
Benjamini-Hochberg procedure by nSolver software (NanoString Technologies).
Figure 8. Schematic diagram illustrating the mechanism by which the binding of anti-GRP78 autoantibodies to csGRP78 on lesion-resident ECs acceler-
ates atherosclerotic lesion growth via NF-κB activation. Conditions of ER stress in the early stages of atherosclerosis lead to the translocation of GRP78 
from the ER to the cell surface. The presentation of csGRP78 induces an immunological response that drives the production of anti-GRP78 autoantibodies. 
Binding of anti-GRP78 autoantibodies to ECs activates the NF-κB pathway, leading to increased expression of adhesion molecules and the progression of 
atherosclerotic plaque.
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mRNA quantification by quantitative real-time PCR. Total RNA was isolated from HAECs with the 
RNeasy mini kit (Qiagen) and reverse-transcribed by using the High-Capacity cDNA Reverse Transcription 
kit (Applied Biosystems). Quantitative real-time PCR was performed in triplicate with Fast SYBR Green 
Master Mix (Applied Biosystems) under standard conditions. The primer sequences used are listed in Sup-
plemental Table 1. β2 Microglobulin (B2M) and 18S were used as housekeeping genes.
Analysis of  serum anti-GRP78 autoantibody titers. Autoantibodies against GRP78 in mouse sera were deter-
mined by ELISA, as described previously (16). Our approach was to identify the antibodies recognizing the 
N-terminal of  GRP78 by using a previously characterized synthetic peptide that mimics amino acids Leu98-
Leu115 in GRP78 (16). Briefly, 96-well plates were coated with the CNVSKDSC peptide conjugated to KLH 
(5 mg/ml), blocked with PBS-Tween containing 3% BSA, and incubated overnight with serum samples at a 
1:100 dilution. Plates were incubated with anti-mouse IgG conjugated to alkaline phosphatase and developed 
with an alkaline phosphatase substrate. Absorbance was read at 405 nm. All assays were performed in tripli-
cate and analyzed relative to a standard sample to correct for plate-to-plate variation.
Cell adhesion assay. HAECs were seeded into 24-well fluorescence plates and allowed to adhere over-
night. Cells were treated without or with Tm (2.5 mg/ml, 24 hours), followed by the indicated conditions. 
U937 cells (ATCC) were washed and resuspended at 1 × 106 cells/ml in HBSS containing HEPES with 
BCECF-AM (4 mM, MilliporeSigma) for 30 minutes at room temperature. Cells were washed with growth 
media to remove excess fluorophore and resuspended at 1 × 106 cells/ml in RPMI lacking phenol red 
(catalog 11835; Life Technologies). Treated HAECs were washed with PBS, and 50 μl BCECF-AM–load-
ed U937 cells were added to each well. Fluorescence was measured at 439 nm excitation to determine 
the maximum signal for each well. After 30 minutes of  incubation at 37°C, 3 washes were performed to 
remove nonadherent cells. Fluorescence was measured a second time as described above. Adhesion was 
determined for each well as a percentage relative to the maximum fluorescence detected prior to washing. 
All assays were performed in triplicate.
En face immunofluorescence. Female ApoE–/– mice at 18 weeks of  age were injected i.v. in the tail vein with 
10 mg b-anti-GRP78 autoantibody or 10 mg b-IgG. Mice were euthanized after 30 minutes as described 
above. The aortic arch was dissected and cut open longitudinally. The aortas were blocked with 10% goat 
serum and incubated overnight with rat anti-CD31 (1:200; BD Pharmingen), followed by PBS washes and 
anti-rat Alexa Fluor 488 (1:200; Life Technologies) and streptavidin-conjugated Alexa Fluor 594 (1:200; 
Life Technologies) for 30 minutes. Nuclei were stained with DAPI (MilliporeSigma). The aortas were 
mounted on slides with ProLong Gold Antifade Mountant (Life Technologies) and imaged under a Zeiss 
Axioplan fluorescent microscope (Carl Zeiss Canada). Regions with and without lesions were identified 
based on published anatomical locations relative to the lesser and greater curvature area (20, 57).
Statistics. Values are expressed as mean ± SD. Statistical analysis was performed by using an unpaired 
2-tailed Student’s t test or ANOVA. When significance was attained using ANOVA, a Tukey’s post hoc test was 
used to determine specific differences. Statistical significance was defined as P < 0.05 unless otherwise specified.
Study approval. All animal studies and procedures were reviewed and approved by the McMaster Uni-
versity Animal Research Ethics Board (AUP 16-12-43). Patients were screened for CAD based on coronary 
CT angiogram. The average age of  CAD and non-CAD participants was 62.7 and 53.8 years, respectively. 
This study was approved by the human Research Ethics Board at the University of  Ottawa, Ottawa, Ontar-
io, Canada (protocol 20160605).
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